The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to explore the value of molecular residual disease (MRD)
monitoring based on ctDNA in advanced or metastatic pancreatic cancer. The main questions it
aims to answer are:
- prognostic value of baseline MRD;
- the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood
derived from participants will be obtained for MRD test before first-line chemotherapy
initiation and at the first imaging assessment after chemotherapy.